Skip to main content
. 2018 Dec 14;9(98):37080–37096. doi: 10.18632/oncotarget.26354

Figure 5. Effect of niraparib and olaparib on tumor volume in BRCA2mut OV5311 ovarian cancer PDX model.

Figure 5

Tumor volume of the OV5311 model treated with niraparib or olaparib at the maximum tolerated dose. Niraparib was administered at 75 mg/kg daily for 78 days. Olaparib was administered at 75 mg/kg once daily for 44 days and then 4 mice from this group were switched to 50 mg/kg of niraparib once daily for 34 days, while the remaining 5 mice continued with 75 mg/kg of olaparib.